Onconic Therapeutics
↗Gangnam-gu, Seoul, South Korea
Onconic Therapeutics is a South Korean biopharmaceutical company founded in 2020 and based in Seoul. As a subsidiary of Jeil Pharmaceutical (44.95% ownership), Onconic specializes in developing innovative treatments for oncology and gastrointestinal diseases with high unmet medical needs. The company has successfully launched Jaqbo (zastaprazan), a next-generation potassium-competitive acid blocker (P-CAB) approved by Korea's MFDS in April 2024, and is advancing a robust pipeline of oncology candidates including nesuparib, a dual-target PARP/tankyrase inhibitor for multiple cancer indications. Following its IPO on KOSDAQ in December 2024 (ticker: 476060), Onconic has rapidly expanded its market capitalization and is now pursuing global partnerships to commercialize its drug candidates.
CLASSIFICATION
SIZE & FINANCIALS
Employees:11-50
Revenue:₩53.3B (2025 actual) vs ₩16.2B forecasted
Founded:2020
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$34.9M
Investors:Stonebridge Ventures, Premier Partners, BNH Investment, DAOL Investment, Korea Development Bank, K2 Investment Partners, Aju IB Investment, SL Investment, DT& Investment, Jeil Pharmaceutical (major shareholder)
STOCK
Exchange:KOSDAQ
Ticker:476060
Market Cap:~₩970B (~$665M USD equivalent as of December 2025)
PIPELINE
Stage:Approved|Phase 2|Phase 3
Lead Drug Stage:Commercial (Jaqbo approved April 2024)
Modalities:Small molecule, PARP inhibitor, P-CAB (Potassium-competitive acid blocker)
Active Trials:13
Trial Phases:Phase 1: 1 | Phase 2: 4 | Phase 3: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Jeil Pharmaceutical (98.5% ownership through subsidiary structure)
Key Partnerships:Celltrion (ovarian cancer combination therapy with Vegzelma, 2025), Jeil Pharmaceutical (domestic sales and distribution), Dong-A ST (co-promotion partner for Jaqbo)
COMPETITION
Position:Challenger|Emerging
Competitors:Jazz Pharmaceuticals, Karyopharm, C4 Therapeutics, Other Korean biotech: STCube, Abion, LigaChem Biosciences, Etnova Therapeutics, Pin Therapeutics, Rznomics
LEADERSHIP
Key Executives:
John Kim (Kim Jung-hoon) - CEO
Yoon Tae Young - Inside Director
Shin Dong Jun - Executive Vice President/Inside Director
Shim Hye Seok - Managing Director/Inside Director
Kim Kyu Sik - Outside Director
Hong Nam Gi - Outside Director
Lee Kwang Yeol - Standing Auditor
Board Members:Yoon Tae Young, Shin Dong Jun, Shim Hye Seok, Kim Kyu Sik, Hong Nam Gi, Lee Kwang Yeol (Auditor)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Onconic Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Onconic Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.